covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | June 10, 2021 | News story | |   

The past week has seen lots of vaccine-related news, Pfizer-BioNTech has expanded its COVID-19 vaccine study in children under 12, WHO has approved China’s Sinovac under an emergency use listing, Regeneron’s COVID antibody EUA has been reduced to a lower dose by the FDA, the MHRA has confirmed registeration of Avacta’s lateral flow test, and we have a general UK vaccine roundup.

 1. Pfizer to expand COVID vaccine study in children under 12 – Published 10/05/2021

Pfizer has announced that it will begin large-scale testing of its COVID-19 vaccine after selecting a lower dose of the jab in the Phase I study.

Advertisement

 2. UK vaccination update – Published 07/05/21

 With 21 June fast approaching, and the Delta variant rising in the UK, here’s the latest vaccine update.

 3. MHRA confirms registration of Avacta’s lateral flow test– Published – 07/06/2021

Avacta has announced that the MHRA has confirmed registration of the AffiDX SARS-CoV-2 antigen lateral flow test, which allows the company to place the product on the market in the UK for professional use.

 4. Regeneron’s COVID-19 antibody EUA reduced to lower dose by FDA – Published 07/06/21

 The FDA has updated the Emergency Use Authorisation (EUA) for Regeneron Pharmaceuticals’ COVID-19 antibody cocktail, REGEN-COV, halving the dose from 2,400mg to 1,200mg.

 5. WHO approves China’s Sinovac COVID-19 vaccine – Published 03/06/21

China’s Sinovac COVID-19 vaccination has received an emergency use listing (EUL) from the WHO.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content